دورية أكاديمية
Social Determinants of Health in People Living with Psychiatric Disorders: The Role of Pharmacists.
| العنوان: | Social Determinants of Health in People Living with Psychiatric Disorders: The Role of Pharmacists. |
|---|---|
| المؤلفون: | Cobb CD; Capital Consulting, Billings, Montana, USA., Allen SN; PCOM Georgia School of Pharmacy, Suwanee, Georgia, USA., Cusimano JM; Pharmacy Practice Department, Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, Virginia, USA., Ding M; Kaiser Permanente, Los Angeles, California, USA., Eloma AS; Kings County Hospital, NYC Health + Hospitals, Brooklyn, New York, USA., Ott CA; Department of Pharmacy Practice, Purdue University/Eskenazi Health, Indianapolis, Indiana, USA., Tallian KB; Scripps Mercy Hospital, San Diego, CA, San Diego, California, USA. |
| المصدر: | Health equity [Health Equity] 2023 Apr 19; Vol. 7 (1), pp. 223-234. Date of Electronic Publication: 2023 Apr 19 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 101708316 Publication Model: eCollection Cited Medium: Internet ISSN: 2473-1242 (Electronic) Linking ISSN: 24731242 NLM ISO Abbreviation: Health Equity Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: New Rochelle, NY : Mary Ann Liebert, Inc., [2017]- |
| مستخلص: | Introduction: Social determinants of health (SDOH) affect outcomes of people living with psychiatric disorders, including substance use disorders. As experts in medication optimization, pharmacists play a vital role in identifying and addressing medication-related problems associated with SDOH. However, there is a paucity of literature on how pharmacists can be part of the solution. Objective: The purpose of this article is to provide a narrative review and commentary on the intersection between SDOH, medication-related outcomes in people living with psychiatric disorders, and the role of pharmacists in addressing them. Method: The American Association of Psychiatric Pharmacists appointed an expert panel to research the issue, identify barriers, and develop a framework for including pharmacists in addressing medication therapy problems associated with SDOH in people with psychiatric disorders. The panel used Healthy People 2030 as the framework and sought input from public health officials to propose solutions for their commentary. Results: We identified potential connections between SDOH and their impact on medication use in people with psychiatric disorders. We provide examples of how comprehensive medication management can afford opportunities for pharmacists to mitigate medication-related problems associated with SDOH. Conclusion: Public health officials should be aware of the vital role that pharmacists play in addressing medication therapy problems associated with SDOH to improve health outcomes and to incorporate them in health promotion programs. Competing Interests: C.D.C. is a stockholder in Abbott, Amgen, Astra Zeneca, Eli Lilly, Gilead, Johnson & Johnson, Merck, Moderna, Proctor and Gamble, Moderna, and Seagen. C.A.O. is an expert panelist for the Indiana University School of Medicine Project ECHO for Opioid Use Disorders; an expert panelist for the Indiana University Fairbanks School of Public Health Project ECHO for LGBTQ+ Health; serves on the Indiana Medicaid Drug Utilization Review Board, Mental Health Quality Advisory Committee, and Psychotropic Medication Advisory Committee; is a consultant for Wolters-Kluwer/Lexi-Comp; is President of the NAMI West Central Indiana Board of Directors; serves on the Psychopharmacology Consultation Team—Indiana University School of Medicine Department of Psychiatry, Indiana Department of Child Services; and receives grant funding from SAMHSA. No other author reports any relevant disclosures. (© Carla D. Cobb et al., 2023; Published by Mary Ann Liebert, Inc.) |
| References: | Pediatr Res. 2016 Jan;79(1-2):227-33. (PMID: 26460523) Ann Pharmacother. 2018 Aug;52(8):810-818. (PMID: 29519141) Health Aff (Millwood). 2021 May;40(5):802-811. (PMID: 33939507) Pharmacoepidemiol Drug Saf. 2015 Nov;24(11):1197-206. (PMID: 26132170) Drug Alcohol Depend. 2021 Aug 1;225:108784. (PMID: 34049104) J Clin Psychiatry. 2021 May 4;82(3):. (PMID: 34004086) J Gen Intern Med. 2012 Oct;27(10):1361-7. (PMID: 22618581) Curr Med Res Opin. 2014 Aug;30(8):1643-55. (PMID: 24730586) Pharmacotherapy. 2014 Dec;34(12):1336-40. (PMID: 25329409) Med Care Res Rev. 2018 Dec;75(6):721-745. (PMID: 29148328) Public Health Rep. 2018 Nov/Dec;133(1_suppl):24S-34S. (PMID: 30426871) Ment Health Clin. 2022 Apr 14;12(2):65-76. (PMID: 35582319) Annu Rev Public Health. 2011;32:381-98. (PMID: 21091195) Am J Emerg Med. 2020 Feb;38(2):300-304. (PMID: 31387811) MMWR Morb Mortal Wkly Rep. 2019 Nov 08;68(44):999-1005. (PMID: 31697656) J Gen Intern Med. 2021 May;36(5):1359-1370. (PMID: 33515188) Blood. 2021 Jan 7;137(1):13-15. (PMID: 33181819) J Am Pharm Assoc (2003). 2020 Sep - Oct;60(5S):S98-S106. (PMID: 32665098) Curr Psychiatry Rep. 2018 Sep 17;20(11):95. (PMID: 30221308) Pharmacotherapy. 2013 Aug;33(8):888-91. (PMID: 23625823) Am J Manag Care. 2019 Sep;25(9):450-456. (PMID: 31518095) J Am Med Inform Assoc. 2019 Aug 1;26(8-9):895-899. (PMID: 31329877) Health Aff (Millwood). 2014 Nov;33(11):1958-65. (PMID: 25367990) J Am Pharm Assoc (2003). 2022 Nov-Dec;62(6):1816-1822.e2. (PMID: 35965233) J Am Pharm Assoc (2003). 2021 Jul-Aug;61(4S):S154-S160. (PMID: 33451969) Addict Sci Clin Pract. 2019 Sep 2;14(1):30. (PMID: 31474225) Ment Health Clin. 2019 Jul 01;9(4):269-274. (PMID: 31293846) Res Social Adm Pharm. 2016 Jan-Feb;12(1):78-90. (PMID: 26004019) Psychiatr Serv. 2018 Feb 1;69(2):224-227. (PMID: 29032704) Schizophr Bull. 2007 Sep;33(5):1221-4. (PMID: 17170061) J Behav Health Serv Res. 2013 Jul;40(3):367-77. (PMID: 23702611) J Am Pharm Assoc (2003). 2018 Jul - Aug;58(4S):S24-S29.e2. (PMID: 30006184) Aust N Z J Psychiatry. 2010 Dec;44(12):1057-63. (PMID: 20973623) Am J Pharm Educ. 2020 Nov;84(11):8241. (PMID: 34283757) BMC Psychiatry. 2012 Aug 02;12:99. (PMID: 22856540) Psychiatr Serv. 2021 Jul 1;72(7):794-801. (PMID: 33940946) |
| فهرسة مساهمة: | Keywords: clinical pharmacists; community pharmacists; healthy people programs; psychiatric disorders; public health; social determinants of health |
| تواريخ الأحداث: | Date Created: 20230425 Latest Revision: 20230426 |
| رمز التحديث: | 20230428 |
| مُعرف محوري في PubMed: | PMC10122249 |
| DOI: | 10.1089/heq.2022.0189 |
| PMID: | 37096056 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2473-1242 |
|---|---|
| DOI: | 10.1089/heq.2022.0189 |